C O M M U N I C A T I O N S
Scheme 1
(8) Rasolonjanahary, R.; Se´venet, T.; Voegelein, F. G.; Kordon, C. Eur. J.
Pharmacol. 1995, 285, 19-23.
(9) (a) Link, J. T.; Overman, L. E. J. Am. Chem. Soc. 1996, 118, 8166-
8167. (b) Overman, L. E.; Paone, D. V.; Stearns, B. A. J. Am. Chem.
Soc. 1999, 121, 7702-7703. (c) Overman, L. E.; Larrow, J. F.; Stearns,
B. A.; Vance, J. M. Angew. Chem., Int. Ed. 2000, 39, 213-215.
(10) (a) Ashimori, A. Bachand, B.; Overman, L. E.; Poon, D. J. J. Am. Chem.
Soc. 1998, 120, 6477-6487. (b) Ashimori, A.; Bachand, B.; Calter, M.
A.; Govek, S. P.; Overman, L. E. J. Am. Chem. Soc. 1998, 120, 6488-
6499. (c) Oestreich, M.; Dennison, P. R.; Kodanko, J. J.; Overman, L. E.
Angew. Chem., Int. Ed. 2001, 40, 1439-1442.
(11) This approach represents an uncommon variant of two-directional
synthesis.12 In the present case, reagent control is employed to simulta-
neously functionalize both termini.13
many complex polypyrrolidinoindoline alkaloids and their analogues
to be obtained by sterocontrolled chemical synthesis.
Acknowledgment. We thank NIH (HL-25854) for financial
support, Professor Franc¸oise Gue´ritte-Voegelein for a sample of
quadrigemine C, and Mr. Jeremy Kodanko for advice and develop-
ing the synthesis of 8. Fellowship support to J.T.L. (American
Cancer Society), B.A.S. (Bristol-Myers Squibb), and A.D.L.
(Pharmacia) is gratefully acknowledged.
Supporting Information Available: Experimental procedures for
1
the preparation of 1, 3, 5, 6, 7, 8, 9, 10, and 11; copies of H and 13C
(12) For reviews, see: (a) Schreiber, S. L. Chem. Scr. 1987, 27, 563-566. (b)
Poss, C. S.; Schreiber, S. L. Acc. Chem. Res. 1994, 27, 9-17. (c)
Magnuson, S. R. Tetrahedron 1995, 51, 2167-2213.
NMR spectra of these compounds (PDF). This material is available
(13) For the first report of this strategy, see: Wang, Z.; Descheˆnes J. Am.
Chem. Soc. 1992, 114, 1090-1091.
References
(14) Iwao, M.; Kuraishi, T. Org Synth. 1996, 73, 85-93.
(15) Stannane 8 was synthesized in four steps from commercially available
(1) Current addresses: (a) Abbott Laboratories, 100 Abbott Park Road, Abbott
Park, IL 60064-6098. (b) Merck Research Laboratories, 3535 General
Atomics Court, San Diego, CA 92121.
3H-benzooxazol-2-one (see Supporting Information).
(16) Farina, V.; Krishnan, B. J. J. Am. Chem. Soc. 1991, 113, 9585-9595.
(2) Anthoni, U.; Christophersen, C.; Nielsen, P. H. In Alkaloids: Chemical
and Biological PerspectiVes; Pelletier, S. W., Ed.; Wiley: New York,
1999; Vol. 14, pp 163-236.
(17) (a) Liebeskind, L. S.; Fengl, R. W. J. Org. Chem. 1990, 55, 5359-5364.
(b) Han, X.; Stoltz, B. M.; Corey, E. J. J. Am. Chem. Soc. 1999, 121,
7600-7605.
(3) Libot, F.; Miet, C.; Kunesch, N.; Poisson, J. E.; Pusset, J.; Se´venet, T. J.
Nat. Prod. 1987, 50, 468-473.
(18) The catalyst generated from Pd(OAc)2 and (R)-BINAP was less selective
and provided 10 in lower yield and 65% ee.
(4) Verotta, L.; Pilati, T.; Tatø, M.; Eilsabetsky, E.; Amador, T. A.; Nunes,
D. S. J. Nat. Prod. 1998, 61, 392-396.
(19) Four dioxindole products are possible, two meso isomers and a pair of
C1-symmetric enantiomers.
(20) Sodium (in ethanol) was the reductant employed in the first reported
conversion of a 3-(2-aminoethyl)oxindole to a pyrrolidinoindoline: Julian,
P. L.; Pikl, J. J. Am. Chem. Soc. 1935, 57, 539-544.
(5) Gue´ritte-Voegelein, F.; Se´venet, T.; Pusset, J.; Adeline, M. T.; Gillet, B.;
Beloeil, J. C.; Guenard, D.; Potier, P. J. Nat. Prod. 1992, 55, 923-930.
(6) Jannic, V.; Gue´ritte, F.; Lapre´vote, O.; Serani, L.; Martin, M.-T.; Se´venet,
T.; Potier, P. J. Nat. Prod. 1999, 62, 838-843.
(7) Saad, H.-E. A.; El-Sharkawy, S. H.; Shier, W. T. Planta Med. 1995, 61,
313-316.
JA0267425
9
J. AM. CHEM. SOC. VOL. 124, NO. 31, 2002 9009